Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04906382
Title Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Floor Backes

uterine carcinosarcoma

endometrial carcinoma


Carboplatin + Paclitaxel + Tislelizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from for the field